iCAD is a global leader in advanced breast cancer detection solutions built on artificial intelligence that empower radiologists to find cancers earlier while improving reading workflow. Our Breast Health Solutions suite delivers powerful detection and workflow solutions for 2D and 3D mammography.
Featuring presentations by Key Opinion Leaders who discuss the current landscape for digital breast tomosynthesis (DBT) and the potential for iCAD's recently introduced ProFound AI Risk, the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation based solely on a screening mammogram.
December 29, 2020
iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption
» View all news »
Digital breast tomosynthesis (DBT) is rapidly replacing 2D mammography in breast cancer screening because of the clinical value it offers in cancer detection. However, it presents significant workload challenges for radiologists, which can affect patient care. ProFound AI® is clinically proven to assist radiologists by improving cancer detection, decreasing reading times and reducing false positives and costly patient recalls.
Inform, connect and engage. We invite you to engage with us to participate on the topic of cancer detection solutions, patient stories, clinical expertise.
The New Normal - The Imaging Landscape in Late-Stage Pandemic Days
Improving reading time of digital breast tomosynthesis with concurrent computer aided detection.
Speak to a specialist today at 1.866.280.2239
Precise and Powerful Healthcare Solutions
© 2020, iCAD Inc. All rights reserved. iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.